| Autor: |
Laurel B. Darragh, Michael M. Knitz, Junxiao Hu, Eric T. Clambey, Jennifer Backus, Andrew Dumit, Von Samedi, Andrew Bubak, Casey Greene, Timothy Waxweiler, Sanjana Mehrotra, Shilpa Bhatia, Jacob Gadwa, Thomas Bickett, Miles Piper, Kareem Fakhoury, Arthur Liu, Joshua Petit, Daniel Bowles, Ashesh Thaker, Kimberly Atiyeh, Julie Goddard, Robert Hoyer, Adrie Van Bokhoven, Kimberly Jordan, Antonio Jimeno, Angelo D’Alessandro, David Raben, Jessica D. McDermott, Sana D. Karam |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Nature Cancer. 3:1300-1317 |
| ISSN: |
2662-1347 |
| Popis: |
Five-year survival for human papilloma virus-unrelated head and neck squamous cell carcinomas remain below 50%. We assessed the safety of administering combination hypofractionated stereotactic body radiation therapy with single-dose durvalumab (anti-PD-L1) neoadjuvantly (n = 21) (NCT03635164). The primary endpoint of the study was safety, which was met. Secondary endpoints included radiographic, pathologic and objective response; locoregional control; progression-free survival; and overall survival. Among evaluable patients at an early median follow-up of 16 months (448 d or 64 weeks), overall survival was 80.1% with 95% confidence interval (95% CI) (62.0%, 100.0%), locoregional control and progression-free survival were 75.8% with 95% CI (57.5%, 99.8%), and major pathological response or complete response was 75% with 95% exact CI (51.6%, 100.0%). For patients treated with 24 Gy, 89% with 95% CI (57.1%, 100.0%) had MPR or CR. Using high-dimensional multi-omics and spatial data as well as biological correlatives, we show that responders had: (1) an increase in effector T cells; (2) a decrease in immunosuppressive cells; and (3) an increase in antigen presentation post-treatment. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink